Axitinib Licensed by Pfizer

Catalog No.S1005

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Price Stock Quantity  
USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Axitinib Chemical Structure

Axitinib Chemical Structure
Molecular Weight: 386.47

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

VEGFR Inhibitors with Unique Features

Product Information

  • Compare VEGFR Inhibitors
    Compare VEGFR Products
  • Research Area
  • Axitinib Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Targets VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)

 View  More

IC50 0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM
In vitro Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellM2Ttb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfmVpFKSzVyPUCuNFAxODVzMzFOwG0>NV7uSJZ4W0GQR1XS
NCI-H1703NGLMTndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1f4ZmlEPTB;MD6wNFA6ODJizszNM1rIRnNCVkeHUh?=
KASUMI-1NXfybJdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTBwMEC2PFIh|ryPMmfxV2FPT0WU
CGTH-W-1NGTuT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLuTWM2OD1yLkCwO|IzKM7:TR?=MmH4V2FPT0WU
A204NVHSPYN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTBwMEC5PVIh|ryPNFOydnlUSU6JRWK=
HOP-62NH\2d2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TSSGlEPTB;MD6xNFg{PiEQvF2=NWfQNpdPW0GQR1XS
H-EMC-SSM3TV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHVU2pKSzVyPUCuNVExODVizszNM2j5c3NCVkeHUh?=
KU812M1TScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwMU[1O|ch|ryPM3vDWnNCVkeHUh?=
EM-2NUjXPXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXxSHNKSzVyPUCuNVY5OTZizszNMnLNV2FPT0WU
LAMA-84NIGwNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTBwMUe2OlUh|ryPMYrTRW5ITVJ?
JARMmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTBwMkO5PFkh|ryPNFXlVXBUSU6JRWK=
G-361MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTBwM{KzNlUh|ryPMmLLV2FPT0WU
KG-1NE\CR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\Ke2xnUUN3ME2wMlM4PjR{IN88US=>M4[yRXNCVkeHUh?=
BV-173M4n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLnTWM2OD1yLkO5N|Ih|ryPMnvaV2FPT0WU
K5MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTBwNEKxNlch|ryPNEPWXIJUSU6JRWK=
MEG-01MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\CZmlEPTB;MD60NlM3OSEQvF2=Mnz6V2FPT0WU
MFM-223M1S4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XPcmlEPTB;MD60OFc4PiEQvF2=NHu0TZlUSU6JRWK=
BE-13M{ftVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTBwNUGwNFgh|ryPNG\zTlZUSU6JRWK=
NEC8NYLW[Wd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XxfGlEPTB;MD63NlEyOyEQvF2=NXXOOmJ1W0GQR1XS
SW756M{jDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\tTWM2OD1yLkm5PFQ3KM7:TR?=MVnTRW5ITVJ?
A2780NWDn[m9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFi4SWVKSzVyPUGuNFEyPDZizszNM1;aXnNCVkeHUh?=
NB14NHj2VZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPlVWpRUUN3ME2xMlAyQDBzIN88US=>NEDSd|lUSU6JRWK=
H4Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEL0ZopKSzVyPUGuNFY1OjJizszNM{[yW3NCVkeHUh?=
SK-OV-3M1;zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTFwME[2N|Mh|ryPNWiyNodTW0GQR1XS
AN3-CAM1HINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPNdolKSzVyPUGuNFg{QDlizszNNH;XfHdUSU6JRWK=
A427NVnZZm1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{n6NmlEPTB;MT6xNFM5OSEQvF2=NUO3TFVxW0GQR1XS
ES7NXfnUmUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYf5[nlkUUN3ME2xMlEyOzN2IN88US=>NYrZXW9{W0GQR1XS
AGSNW\wbFM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLySnhKSzVyPUGuNVE{QTVizszNNYnRS3pIW0GQR1XS
G-402M4G0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TJ[mlEPTB;MT6xOFY6PCEQvF2=MkHpV2FPT0WU
ES5Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUL5XlFmUUN3ME2xMlE4OjR6IN88US=>MmWyV2FPT0WU
DELNYXVe|ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmf6TWM2OD1zLkK1OFU4KM7:TR?=NHvCO5RUSU6JRWK=
NB10NIDB[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzSW4ltUUN3ME2xMlMzPTV5IN88US=>MWnTRW5ITVJ?
NCI-H1581MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XkVmlEPTB;MT6zPVA1OiEQvF2=M3jDUXNCVkeHUh?=
D-566MGNWftenNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTFwNEC2PFMh|ryPM2nPRXNCVkeHUh?=
LXF-289NGfxRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{O3UWlEPTB;MT60N|k6PiEQvF2=MWLTRW5ITVJ?
BT-549MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTFwNU[5NFkh|ryPMlXJV2FPT0WU
NKM-1NWXBXXJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPlTmtZUUN3ME2xMlYxPTV4IN88US=>MXXTRW5ITVJ?
SW780NX;ObZRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojVTWM2OD1zLk[1NVU5KM7:TR?=NILje3NUSU6JRWK=
NCI-H292NWj5U41FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHTTWM2OD1zLk[2N|g{KM7:TR?=NYXFZZJGW0GQR1XS
HMV-IIMmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYPqTIxDUUN3ME2xMlcxPDh6IN88US=>MkfHV2FPT0WU
ALL-POM2e4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnvhTWM2OD1zLkiwNFE2KM7:TR?=NUDDc4lKW0GQR1XS
UACC-257MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLsTWM2OD1zLkiyNVY{KM7:TR?=Mn\iV2FPT0WU
PA-1NWPOOVNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTFwOEK3NlUh|ryPM3TXOXNCVkeHUh?=
HD-MY-ZMlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjRd5pKSzVyPUGuPFYzQDFizszNMWLTRW5ITVJ?
HSC-4MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3Tse2lEPTB;MT65N|g{QSEQvF2=MoriV2FPT0WU
GCTNWLaVXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTJwMEC5NVYh|ryPM1z0fnNCVkeHUh?=
RT-112NVLrNmpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTJwMUO0NlQh|ryPMlvPV2FPT0WU
A172MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moq2TWM2OD1{LkGzOlA3KM7:TR?=MULTRW5ITVJ?
HCE-TM172[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rpbGlEPTB;Mj6yNFU6QCEQvF2=NFO3V4lUSU6JRWK=
YH-13NHLwSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{SwcWlEPTB;Mj6yNVY4OSEQvF2=M1HhO3NCVkeHUh?=
DK-MGNVvSS2t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTJwMkO4N|Qh|ryPNF[3c4RUSU6JRWK=
ACNNF;n[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTJwMkO4O|Uh|ryPNYnMeVFnW0GQR1XS
VA-ES-BJNXruSGlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTJwMkS5OVch|ryPNWm5T2cyW0GQR1XS
L-363NGm2XGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnhTWM2OD1{LkK4NFYyKM7:TR?=MlX1V2FPT0WU
HuH-7NUmzW2NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvNTWM2OD1{LkSyNVY2KM7:TR?=MmT5V2FPT0WU
A4-FukM1\ifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXS3foQ3UUN3ME2yMlQ4OTZ6IN88US=>NIXvRYhUSU6JRWK=
T-24MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPBTWM2OD1{LkS4NFM4KM7:TR?=NYXuSFE2W0GQR1XS
GOTONGHuUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nJcmlEPTB;Mj61N|AyOyEQvF2=NWfncIdiW0GQR1XS
MV-4-11NGXCOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTJwNUmxOlkh|ryPNXuyN5pXW0GQR1XS
DMS-114MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGT2dIpKSzVyPUKuOlY{PDVizszNMYrTRW5ITVJ?
MHH-NB-11M1\tUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\yTWM2OD1{LkewNlk6KM7:TR?=NV\oTmpbW0GQR1XS
CHP-212MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlzSTWM2OD1{LkiyNFkyKM7:TR?=M{f1UnNCVkeHUh?=
DMS-273NEjOU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPIUmlDUUN3ME2yMlkxOjB5IN88US=>M{fpWXNCVkeHUh?=
SF295NWP4eo1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TDeGlEPTB;Mz6wNlU6PyEQvF2=NYfCVZZbW0GQR1XS
NCI-H1563MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGOxZplKSzVyPUOuNVUxODVizszNMl23V2FPT0WU
NCI-H446NEX4TpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX;JR|UxRTNwMkK4NFUh|ryPNGfvbplUSU6JRWK=
HCC1806MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\mXWFKSzVyPUOuNlc3PTdizszNNVrufndIW0GQR1XS
SF126M3fNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPvW|RQUUN3ME2zMlMxODF5IN88US=>NYnuc3hQW0GQR1XS
SW982NU[3bVNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWG1c5RLUUN3ME2zMlM{QDd3IN88US=>MYnTRW5ITVJ?
ES8MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHuW4RKSzVyPUOuN|Q6QTlizszNM3fXTnNCVkeHUh?=
SCC-4MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fuO2lEPTB;Mz61NFM6PiEQvF2=M2rZeHNCVkeHUh?=
RPMI-8226MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHoUZA1UUN3ME2zMlYzPjF4IN88US=>M3:xc3NCVkeHUh?=
EW-11MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7jTWM2OD1|Lk[zNFIzKM7:TR?=MX\TRW5ITVJ?
COR-L105MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\TXmlEPTB;Mz62N|M{PCEQvF2=NUXTOmhlW0GQR1XS
ES1M1y4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTNwOEOwPVQh|ryPNHv5UIhUSU6JRWK=
KMOE-2NF7ZcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTNwOUG4NFgh|ryPNYPCSIVuW0GQR1XS
ABC-1M1vrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3xTWM2OD1|LkmzPVEyKM7:TR?=M3nUenNCVkeHUh?=
NCI-H526MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jEd2lEPTB;Mz65PVEzPiEQvF2=NHn1SHFUSU6JRWK=
HCC1395M3H5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTNwOUm0PFQh|ryPMn;QV2FPT0WU
DU-145NHjTZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfwUZRvUUN3ME20MlEzQDJ3IN88US=>M{nHcXNCVkeHUh?=
JEG-3NXzRepBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTRwMUW5NVYh|ryPNI[2bmlUSU6JRWK=
HCC1187NVTUbmNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHtTWM2OD12LkKxOVk4KM7:TR?=MULTRW5ITVJ?
LC-2-adM4TMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nrWGlEPTB;ND6yNlE4PyEQvF2=Ml\KV2FPT0WU
ONS-76NVrKfnBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGPROlhKSzVyPUSuNlQyQTJizszNNULoT4FlW0GQR1XS
CAL-27M13wSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVLJR|UxRTRwMkSzOFQh|ryPNIO5OHFUSU6JRWK=
8-MG-BANUSyb2t[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTRwMk[2OVgh|ryPM3TkVHNCVkeHUh?=
HGC-27M{XqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4q1SmlEPTB;ND6yPVY3KM7:TR?=MX\TRW5ITVJ?
Hs-578-TNUjhe3poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml20TWM2OD12LkOxOFY5KM7:TR?=MWrTRW5ITVJ?
EW-1NGDDUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoP3TWM2OD12LkWzNFE1KM7:TR?=NV7leIFSW0GQR1XS
SW1573M{PYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fEeGlEPTB;ND61OVE3OyEQvF2=NH\DNWZUSU6JRWK=
SNU-423MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PwdmlEPTB;ND62NFc6KM7:TR?=NWGyVVM1W0GQR1XS
HOSMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLuS5ZVUUN3ME20MlY6PzdizszNNYfSW25LW0GQR1XS
LB1047-RCCM1TWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTRwOEG0NVgh|ryPMXHTRW5ITVJ?
ChaGo-K-1M2W2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDFVlM{UUN3ME20Mlg6ODR6IN88US=>Mo\1V2FPT0WU
A3-KAWNF62dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTRwOUezOVIh|ryPMYHTRW5ITVJ?
CAS-1NYqyW2w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTRwOUm5NFgh|ryPMonYV2FPT0WU
NBsusSRNHXCTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnyS5RKSzVyPUWuNFM2OTRizszNNEm3bWlUSU6JRWK=
KM12M1LOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGriXnBKSzVyPUWuNlk5OjdizszNNWTibFh7W0GQR1XS
NCI-H1155NV\DdWFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIS0SmRKSzVyPUWuN|gyQDVizszNNGj3T|FUSU6JRWK=
EFM-19MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofJTWM2OD13LkSxO|M4KM7:TR?=NI\sTlNUSU6JRWK=
D-392MGMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDhTWM2OD13LkW3PFQ6KM7:TR?=NGDmTHJUSU6JRWK=
JVM-3NEHhRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILIPGFKSzVyPUWuO|I{OjVizszNNHvqZ4VUSU6JRWK=
EW-16M1nMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLjWJVLUUN3ME21Mlc2PTh|IN88US=>MoHlV2FPT0WU
KARPAS-45M{\5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\wTWM2OD13Lki0N|I2KM7:TR?=NXewSYVsW0GQR1XS
NCI-H28NIHGXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTVwOEe5NVgh|ryPNX3IcYdvW0GQR1XS
COLO-829M3nt[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHO0T|FKSzVyPUWuPVE2ODRizszNNVfqeox[W0GQR1XS
KM-H2NIT1Oo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzrepFKSzVyPUWuPVI{QTVizszNM{PadXNCVkeHUh?=
NCI-H82NX:1WnlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfKflhKSzVyPUWuPVI4PzFizszNM1HhWHNCVkeHUh?=
OAW-42MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHaZoxKSzVyPUWuPVg5OjFizszNMXLTRW5ITVJ?
A704NYrZWHhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjLPYYzUUN3ME22MlExPTd2IN88US=>MlyxV2FPT0WU
NCI-H1048MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\DTWM2OD14LkGwOVk6KM7:TR?=NXnwUphJW0GQR1XS
LOXIMVIMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYj4[XFMUUN3ME22MlEyOjR6IN88US=>NUL5U4VTW0GQR1XS
MKN45MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHK[JpKSzVyPU[uNlYxOTZizszNNVqyTVljW0GQR1XS
D-502MGM3;0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzBTWM2OD14LkK4PFU4KM7:TR?=M1L4XHNCVkeHUh?=
HUTU-80NGK4W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFz2XXJKSzVyPU[uOFE3QDhizszNMmnBV2FPT0WU
S-117M17ObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTZwNUCyOlch|ryPM2HyRXNCVkeHUh?=
HCC1569MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PPSmlEPTB;Nj61N|c{PyEQvF2=M1LxWnNCVkeHUh?=
J-RT3-T3-5MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXwNXJKSzVyPU[uOVQ2PzJizszNM3OzPXNCVkeHUh?=
OC-314NUH5[5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfyVlVKSzVyPU[uPVEyPTlizszNMomzV2FPT0WU
SNU-449M1fRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYX5fpZqUUN3ME23MlAyODd{IN88US=>NVvuTVlLW0GQR1XS
NCI-H720NUm5d2VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV7ZNVNUUUN3ME23MlE6OzR3IN88US=>M4L5NXNCVkeHUh?=
KP-N-YSMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTdwMkC3NkDPxE1?NXjafnJzW0GQR1XS
IGROV-1MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnv3TWM2OD15LkOyN|g3KM7:TR?=MWXTRW5ITVJ?
SK-PN-DWMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfOS2FKSzVyPUeuOFgyPSEQvF2=NHjuZmVUSU6JRWK=
HCC1419NYjKZnh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTdwNUOg{txONFfvT41USU6JRWK=
HAL-01M4\WZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrVXJRKSzVyPUeuOlA3PDRizszNNUDweWxQW0GQR1XS
HCC2998Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLGSoVKSzVyPUeuOlA4PDNizszNMYjTRW5ITVJ?
SK-N-FIMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLxTWM2OD15Lk[zNFM{KM7:TR?=MW\TRW5ITVJ?
GI-ME-NMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLVWJJqUUN3ME23MlY1QTN2IN88US=>NGLZSmRUSU6JRWK=
SW1088NYfye5ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{H1T2lEPTB;Nz62OVgzPiEQvF2=MoXzV2FPT0WU
IA-LMNX;RfmlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTdwNki2NVMh|ryPMmPkV2FPT0WU
SK-NEP-1MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTdwNkm2NUDPxE1?NWrOSmU6W0GQR1XS
MDA-MB-415M4LnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTdwOEmxPFYh|ryPNHnaPHRUSU6JRWK=
COLO-800NFi4e5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\LOGlEPTB;Nz65OFQ6OiEQvF2=NV\1cGt7W0GQR1XS
NCI-H2228NGDsR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXtT2hTUUN3ME24MlE2Pzh|IN88US=>NWD6cGdUW0GQR1XS
D-423MGM3rrcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRThwMkG3NkDPxE1?MV;TRW5ITVJ?
TE-1M3XJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnyWoZKSzVyPUiuOFQ{OTZizszNM2jtbHNCVkeHUh?=
NOS-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETONWVKSzVyPUiuOVE2OzRizszNMVrTRW5ITVJ?
8505CMmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rhNmlEPTB;OD62OFgzPCEQvF2=MVHTRW5ITVJ?
HEC-1M1vPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTiSmFQUUN3ME24Mlc5PDN7IN88US=>NX;Fd|Q5W0GQR1XS
TE-11NUTJSIxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4fZRWlEPTB;OD65PVU2OSEQvF2=M4LJW3NCVkeHUh?=
CTB-1NWj0U2JqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DqNGlEPTB;OT6wNVQ{OyEQvF2=M2L2NHNCVkeHUh?=
TGBC11TKBMnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX\NU40zUUN3ME25MlAzOjRzIN88US=>NW\oTo06W0GQR1XS
NB17NFewNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILqeXJKSzVyPUmuNVg5PyEQvF2=NHv6U2RUSU6JRWK=
BeckerNEH1[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDSTWM2OD17LkSxPVQ1KM7:TR?=NUjoV241W0GQR1XS
SN12CMkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\iV2tKSzVyPUmuOFUzOzRizszNNUm1XXp1W0GQR1XS
COLO-320-HSRM1\JdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELLXFZKSzVyPUmuOlAzOzdizszNMWLTRW5ITVJ?
D-283MEDNGPQe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{WxR2lEPTB;OT62N|A4OiEQvF2=MYrTRW5ITVJ?
D-263MGNXPFeXZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTCN|BUUUN3ME25Mlg{Ozh2IN88US=>MXLTRW5ITVJ?
MEL-JUSOMmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYLJR|UxRTlwOUCxNlch|ryPNVvXU|VbW0GQR1XS
T98GNVT3cJlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nxNWlEPTB;OT65NFIxOyEQvF2=NX7nOJB6W0GQR1XS
HLENYnRNIpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHw[VFSUUN3ME25MlkxQTB7IN88US=>NIe5Z45USU6JRWK=
Ca9-22M3HOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTFyLkC2OlUh|ryPMV3TRW5ITVJ?
OS-RC-2M2fncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jJfWlEPTB;MUCuNVA1PSEQvF2=M{K1cnNCVkeHUh?=
T47DMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInHO21KSzVyPUGwMlE2PSEQvF2=M4PyZ3NCVkeHUh?=
GI-1NY\OUodXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTFyLkO1N|Mh|ryPMYjTRW5ITVJ?
NUGC-3MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NICxXFdKSzVyPUGwMlQ1ODJizszNMYPTRW5ITVJ?
MDA-MB-361MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vFPGlEPTB;MUCuOFQ{OiEQvF2=MnjlV2FPT0WU
SCC-15NIDZ[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjo[ohlUUN3ME2xNE41PzF6IN88US=>M1\XUXNCVkeHUh?=
KS-1MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLqTWM2OD1zMD62N|AyKM7:TR?=Mk\DV2FPT0WU
CAL-12TMnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\4TWM2OD1zMD62N|YyKM7:TR?=MXrTRW5ITVJ?
OVCAR-4MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfTTWM2OD1zMD63NFY5KM7:TR?=NWSxVHJXW0GQR1XS
HuP-T4NEnxSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXrJR|UxRTFzLkCzNlgh|ryPMVvTRW5ITVJ?
NCI-H358MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVfJR|UxRTFzLkK2OVch|ryPMUnTRW5ITVJ?
HO-1-N-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LmW2lEPTB;MUGuN|M6QCEQvF2=M1O2cHNCVkeHUh?=
NH-12M1mxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{SycmlEPTB;MUGuOVM4QCEQvF2=MYHTRW5ITVJ?
MOLT-4NUT1[4hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;YO2lEPTB;MUGuOVk5PSEQvF2=MoDPV2FPT0WU
K-562NYjTXGdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEG5blJKSzVyPUGxMlczPDhizszNM2LBdnNCVkeHUh?=
ES6NHLGbJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTHTWM2OD1zMT64OVgyKM7:TR?=NUXGVIJGW0GQR1XS
RO82-W-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTFzLkmwOlQh|ryPNIi1[XRUSU6JRWK=
Ramos-2G6-4C10M4HSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Hi[mlEPTB;MUGuPVMzKM7:TR?=Ml7FV2FPT0WU
23132-87M2rLZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn\qTWM2OD1zMj6wPFIyKM7:TR?=Mnn0V2FPT0WU
A549Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TVN2lEPTB;MUKuN|I5PSEQvF2=MnPmV2FPT0WU
NCI-H23MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTF{LkWwNlYh|ryPMYLTRW5ITVJ?
H9M4XHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnBV4JFUUN3ME2xNk42PTd5IN88US=>M1rGNHNCVkeHUh?=
LB771-HNCMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnze5dJUUN3ME2xNk44PjVizszNNHPid5hUSU6JRWK=
QIMR-WILMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NViyV2E{UUN3ME2xNk45OjV6IN88US=>MXnTRW5ITVJ?
HSC-3M4XFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1H0V2lEPTB;MUKuPVI4PiEQvF2=M3\6N3NCVkeHUh?=
PFSK-1MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHLTWM2OD1zMj65OVA4KM7:TR?=MXHTRW5ITVJ?
ETK-1NXf4Nm1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\tTWM2OD1zMz6wO|c6KM7:TR?=MnfMV2FPT0WU
SW1710M4\peWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrVVnBZUUN3ME2xN{4{PjRzIN88US=>MVfTRW5ITVJ?
COLO-684NVfLVFFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVfJR|UxRTF|LkS1OFEh|ryPMUDTRW5ITVJ?
RPMI-7951MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH72RWpKSzVyPUGzMlUyOzZizszNNFTTOWtUSU6JRWK=
A101DMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTF|LkWzOFkh|ryPMYfTRW5ITVJ?
KE-37MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zCZ2lEPTB;MUOuOVg5PyEQvF2=NYr3PJduW0GQR1XS
SiHaM1GzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjzfo83UUN3ME2xN{45OzR4IN88US=>MmmzV2FPT0WU
NCI-H226NFLUeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXm0O5BCUUN3ME2xN{45QDB6IN88US=>M13LbHNCVkeHUh?=
DBNF;JXldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTF|Lkm5Nlgh|ryPMmPHV2FPT0WU
HT-1197Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1:3c2lEPTB;MUSuNFgxQSEQvF2=NXnWOJptW0GQR1XS
SBC-5MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{m0V2lEPTB;MUSuNVM3OiEQvF2=NXPWS3J4W0GQR1XS
VMRC-RCZM1TZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnoTmZIUUN3ME2xOE42Pzd2IN88US=>MkfTV2FPT0WU
697M2nBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nIfGlEPTB;MUSuOlI4KM7:TR?=Ml\NV2FPT0WU
OMC-1NYHxdmF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nINWlEPTB;MUSuO|g5QCEQvF2=MVzTRW5ITVJ?
SKG-IIIaMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTF2LkiwNFEh|ryPMmT3V2FPT0WU
DOKMo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHlfZpCUUN3ME2xOE46QTN|IN88US=>NWLW[WFnW0GQR1XS
NCI-H2029Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmL2TWM2OD1zNT6zOlAzKM7:TR?=M1vhN3NCVkeHUh?=
NCI-H2009MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF63eXhKSzVyPUG1MlUxQTVizszNM13MbHNCVkeHUh?=
LK-2NIeyVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvFTWM2OD1zNT62OFQ6KM7:TR?=NHniXVRUSU6JRWK=
NCI-H661MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjCTWM2OD1zNT65NFc2KM7:TR?=M{fXfHNCVkeHUh?=
GT3TKBM2LPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PoTWlEPTB;MU[uNFY4PiEQvF2=M1K3eHNCVkeHUh?=
GP5dNGjxb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkPkTWM2OD1zNj6zOFIh|ryPMkPxV2FPT0WU
SK-MEL-2MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\TPJlbUUN3ME2xOk41PDh3IN88US=>M1frSHNCVkeHUh?=
SK-UT-1MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPWcFNoUUN3ME2xOk42PjVizszNM2XyVHNCVkeHUh?=
NB7Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3LpUWlEPTB;MU[uOlk4OSEQvF2=NHvSXnlUSU6JRWK=
NCI-H460M4\2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33zbmlEPTB;MU[uO|MzPiEQvF2=NWnteIZ5W0GQR1XS
8305CMk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTF4Lke4O|ch|ryPMYnTRW5ITVJ?
CaR-1NUm2TJBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHwTWM2OD1zNj64NVEyKM7:TR?=Mle3V2FPT0WU
D-247MGMonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvjPWZjUUN3ME2xOk45PjJ3IN88US=>NUnD[Zp5W0GQR1XS
LoVoM3XTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTF4Lkm0PFgh|ryPNVjSc5lpW0GQR1XS
NCI-H2405NXjicpI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXznXHdKUUN3ME2xO{4yQTB6IN88US=>MULTRW5ITVJ?
AU565M3\iSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrhNo1KSzVyPUG3MlIzPSEQvF2=NVK4dJNMW0GQR1XS
OCI-AML2M130cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLFS4xKSzVyPUG3MlU{OTdizszNM4Hpb3NCVkeHUh?=
22RV1NFnJTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmq5TWM2OD1zNz61PFg1KM7:TR?=NYDQOmR1W0GQR1XS
HT-144NYnn[|FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnf0TWM2OD1zNz62OVk5KM7:TR?=MYTTRW5ITVJ?
HuO9NYfQVHhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnUTWM2OD1zNz63NFMyKM7:TR?=MlrtV2FPT0WU
DaoyNV3QU2JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk[yTWM2OD1zNz63NVg1KM7:TR?=MUXTRW5ITVJ?
SJRH30M3fwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTF5Lki0PFkh|ryPM3;4c3NCVkeHUh?=
CHL-1Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XZZ2lEPTB;MUeuPVI1QSEQvF2=NFrTdnRUSU6JRWK=
J82M3S2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEGyVHdKSzVyPUG3Mlk3OzVizszNMUnTRW5ITVJ?
COR-L23M{T3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzBVZpKSzVyPUG4MlAxOTFizszNM4L2UHNCVkeHUh?=
SNU-C2BMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTF6LkKyO|Yh|ryPNHXhdoRUSU6JRWK=
NCI-H1770M2jaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnBS21MUUN3ME2xPE41PjF3IN88US=>MVjTRW5ITVJ?
MHH-PREB-1M1HLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fte2lEPTB;MUiuOVY6PyEQvF2=MmK4V2FPT0WU
ES3NE\mdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTF6LkW4PFMh|ryPNEK3RWJUSU6JRWK=
MDA-MB-231NEfsZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF36NIJKSzVyPUG4MlY2ODJizszNNI\FZ|ZUSU6JRWK=
MN-60M3O0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\hSG5KSzVyPUG5MlA2QTJizszNMoHlV2FPT0WU
EPLC-272HNWTsSG1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUXXTm5PUUN3ME2xPU4{PzB6IN88US=>MkTBV2FPT0WU
SW948MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDne28xUUN3ME2xPU4{QTN2IN88US=>MnzDV2FPT0WU
MOLT-13NFzEb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnzOoVRUUN3ME2xPU41PTR4IN88US=>NWT0[2hkW0GQR1XS
HL-60M4jXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;2NWlEPTB;MkCuNlE1OSEQvF2=NEjHPHhUSU6JRWK=
CP50-MEL-BMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3WyNmlEPTB;MkCuOFc1QCEQvF2=MnrDV2FPT0WU
NTERA-S-cl-D1MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXDZ3JRUUN3ME2yNE41QTd6IN88US=>MmH5V2FPT0WU
KINGS-1NF;GXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUKzdY45UUN3ME2yNE44QTZ5IN88US=>NXHn[HpWW0GQR1XS
DOHH-2NWO0bVBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7JWFYxUUN3ME2yNE46ODZizszNM33a[nNCVkeHUh?=
BB65-RCCM2fOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnWc4hKSzVyPUKwMlkzQDVizszNMVPTRW5ITVJ?
NB12MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVn4NnQ6UUN3ME2yNU4xOzl2IN88US=>MlLaV2FPT0WU
KY821NVT2Um9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjOWlAxUUN3ME2yNU42QDJizszNM4r2dXNCVkeHUh?=
PSN1MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHoXW5uUUN3ME2yNU43PDV|IN88US=>NGe2NW9USU6JRWK=
EGI-1M1\tWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfP[WpKSzVyPUKxMlc1PTRizszNMX;TRW5ITVJ?
CTV-1MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlm0TWM2OD1{Mj6zNFMyKM7:TR?=MXjTRW5ITVJ?
TI-73NUXtPXJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rMbGlEPTB;MkKuN|Q6QCEQvF2=NFmzd4lUSU6JRWK=
LCLC-103HM4PqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTJ{LkS3OVIh|ryPMmW0V2FPT0WU
D-542MGM2\4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVXaN3hLUUN3ME2yNk42PTV6IN88US=>Ml3DV2FPT0WU
ATN-1NHf5TmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfFTWM2OD1{Mj62OFM6KM7:TR?=M3LNXHNCVkeHUh?=
SK-MEL-1NITXTJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;6VYlIUUN3ME2yNk45OzZ6IN88US=>NGTrZWtUSU6JRWK=
HDLM-2MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHYTWM2OD1{Mz6xOFc5KM7:TR?=MXTTRW5ITVJ?
UM-UC-3M1nSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fkOmlEPTB;MkOuNVk1PCEQvF2=MnX3V2FPT0WU
NCI-H1573MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzYWolQUUN3ME2yN{41PjhzIN88US=>NUHJUXd4W0GQR1XS
NCI-H520MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPWS|hKSzVyPUKzMlQ6PDhizszNMXvTRW5ITVJ?
ESS-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLMV5Y4UUN3ME2yN{45ODV7IN88US=>MVXTRW5ITVJ?
COR-L88M{XqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYWyUIJ6UUN3ME2yN{46PDd3IN88US=>NF2zTlFUSU6JRWK=
TGBC24TKBM1;GWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7wc25[UUN3ME2yOE4xOzF{IN88US=>MX3TRW5ITVJ?
HCC1937NGTTemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTJ2LkGg{txOMVPTRW5ITVJ?
RS4-11NGTXZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF7qV4ZKSzVyPUK0MlE1OiEQvF2=NXHE[ldvW0GQR1XS
HCC38M1zyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3W3V2lEPTB;MkSuNlM6PCEQvF2=MnzCV2FPT0WU
RPMI-2650NFziWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUm2RnMzUUN3ME2yOE43OTZ{IN88US=>M3vyN3NCVkeHUh?=
P12-ICHIKAWAM37GTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjYTWM2OD1{ND62NlU5KM7:TR?=NF7aUXVUSU6JRWK=
YAPCMojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYH5W2hYUUN3ME2yOE45OjF2IN88US=>M2HSSXNCVkeHUh?=
NB13NXPEXI1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7oTWM2OD1{NT6yOlEyKM7:TR?=M3ziU3NCVkeHUh?=
SK-N-ASMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoriTWM2OD1{NT64OVg1KM7:TR?=M4H3cXNCVkeHUh?=
SK-N-DZMn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TCcGlEPTB;Mk[uNFQ6KM7:TR?=MmL4V2FPT0WU
LS-411NNHTN[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjNTWM2OD1{Nj6yNFM5KM7:TR?=MWHTRW5ITVJ?
NCI-H810NHeyRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVy2UYRwUUN3ME2yOk4{OTF{IN88US=>NIrUXnZUSU6JRWK=
NCI-SNU-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTJ4LkW0OVQh|ryPMmfKV2FPT0WU
HHNWHvO|Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmOyTWM2OD1{Nj61OVI6KM7:TR?=NH\lVWNUSU6JRWK=
U-2-OSMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHH[WZKSzVyPUK2Mlc{QDJizszNMkjuV2FPT0WU
SF539Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTJ4LkiwNVgh|ryPMYHTRW5ITVJ?
NCI-H2052M{\ONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITYR5NKSzVyPUK3MlA5PiEQvF2=M{jRSXNCVkeHUh?=
A673MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTJ5LkKxNFIh|ryPMXzTRW5ITVJ?
WM-115NF\4b5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTmTWM2OD1{Nz63O|Y4KM7:TR?=NFTDbZlUSU6JRWK=
SW48NYf2eWF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnMTWM2OD1{Nz64NFA2KM7:TR?=NV\wNpFSW0GQR1XS
NOMO-1NWKxXIpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPLWVNKSzVyPUK3Mlg2OzJizszNMYTTRW5ITVJ?
PC-3Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHOzdWdKSzVyPUK3Mlg6PDFizszNNW\SPJhuW0GQR1XS
UMC-11NYr5bGNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF3nWlJKSzVyPUK3Mlk{PDNizszNNGXXPYpUSU6JRWK=
U-118-MGNF65WYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPqcGVKSzVyPUK4MlAyOjNizszNNYG2UIREW0GQR1XS
NCI-H2452MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXU[G9KSzVyPUK4MlA5OjJizszNMkn2V2FPT0WU
CAMA-1MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrzVHBKSzVyPUK4Mlg2PjRizszNNEDscVlUSU6JRWK=
MC-IXCMojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoCxTWM2OD1{OT6yN|Y3KM7:TR?=NF\QbXBUSU6JRWK=
ES4MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;aZ|FKSzVyPUK5MlMyPzJizszNNHPORoNUSU6JRWK=
BHT-101MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFP1UGFKSzVyPUK5MlMzOSEQvF2=NVjHTHdRW0GQR1XS
KP-4MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHn2VYxKSzVyPUK5MlUyPiEQvF2=M2[2cHNCVkeHUh?=
CAL-54MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHMfpRqUUN3ME2yPU42PDR3IN88US=>NF;qbVVUSU6JRWK=
5637M3LHS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\KW5JKSzVyPUK5MlY1OjFizszNNH7J[2NUSU6JRWK=
MOLT-16MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\uUnlFUUN3ME2yPU44OjZ7IN88US=>MVzTRW5ITVJ?
Ca-SkiNGnOeItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTJ7Lkm0OkDPxE1?M3HHU3NCVkeHUh?=
AsPC-1M3fncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jrTGlEPTB;M{CuNFIyOiEQvF2=Mn;uV2FPT0WU
MSTO-211HM4LNRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlv3TWM2OD1|MD6xOUDPxE1?MoWxV2FPT0WU
L-428MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX[zc21iUUN3ME2zNE41ODVizszNM37xS3NCVkeHUh?=
SW1463MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknsTWM2OD1|MD61N|g{KM7:TR?=MYjTRW5ITVJ?
NCI-H1648MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXaTWM2OD1|MD61OVc1KM7:TR?=M1viOHNCVkeHUh?=
CAKI-1NYi2XJhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfrTWM2OD1|MD63O|AzKM7:TR?=M2jnUXNCVkeHUh?=
YKG-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\LTWM2OD1|MT6wNlY{KM7:TR?=NWHEVIE4W0GQR1XS
A2058NV;jS45yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzQTnljUUN3ME2zNU4yOTZ2IN88US=>MUXTRW5ITVJ?
A375MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfhTWM2OD1|MT6xOlk3KM7:TR?=NVXubnNlW0GQR1XS
SNB75NFewbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHXWZNZUUN3ME2zNU4zPDN3IN88US=>M2XEeHNCVkeHUh?=
SK-HEP-1M3LOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnmSFJKSzVyPUOxMlQzPzFizszNNEjjdm9USU6JRWK=
ME-180M{\UcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlH2TWM2OD1|MT62OVQzKM7:TR?=M2CwTHNCVkeHUh?=
NCI-H209MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUe3NHlwUUN3ME2zNU45OjR5IN88US=>NVrxVoZyW0GQR1XS
HC-1MmG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn2wTWM2OD1|Mj6xOFQ3KM7:TR?=MVTTRW5ITVJ?
LB373-MEL-DNEW1SYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILzfnFKSzVyPUOyMlE6PzFizszNM1\rS3NCVkeHUh?=
SNU-387NYHtNoQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTN{LkOxPVEh|ryPNYPPWphRW0GQR1XS
C32NGXWNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LNNmlEPTB;M{KuN|M2OyEQvF2=Mmn5V2FPT0WU
EW-13MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTN{Lkm0NFgh|ryPMV7TRW5ITVJ?
BFTC-905M2r2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1j0NmlEPTB;M{OuOVE{PiEQvF2=MUTTRW5ITVJ?
NCI-H1299NVuyV45mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHGxSYxKSzVyPUOzMlU3OjFizszNMkXkV2FPT0WU
LU-135M4\Jc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYnJR|UxRTN|LkiwNUDPxE1?NHnSfIRUSU6JRWK=
NCI-H2122MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\2V5JKSzVyPUOzMlk6PjZizszNM4jTcHNCVkeHUh?=
SK-LMS-1Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE[zNVJKSzVyPUO0MlQyODdizszNNY\zdYVOW0GQR1XS
LNCaP-Clone-FGCNV;yPY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTN2Lki1NVUh|ryPMXjTRW5ITVJ?
NCI-H1092NUnMd2hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLqUlkyUUN3ME2zOU4zPzR5IN88US=>MUPTRW5ITVJ?
MS-1NYi5VWZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYezc4FTUUN3ME2zOU4{ODN6IN88US=>MV;TRW5ITVJ?
KYSE-510M3XrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFe3N4FKSzVyPUO1MlUxPDJizszNMn7kV2FPT0WU
NCI-H1793NFTVXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULsfo5iUUN3ME2zOU43PTR3IN88US=>MVLTRW5ITVJ?
MIA-PaCa-2Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPXb4RKSzVyPUO2MlA1QTZizszNMVjTRW5ITVJ?
EW-22MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTN4LkSwO|Ih|ryPNV\mRVg2W0GQR1XS
IGR-1M{\5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHuyVlhKSzVyPUO2MlgyQDRizszNMWDTRW5ITVJ?
HT-1080M2O2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFH4TY1KSzVyPUO3MlEzPSEQvF2=MXXTRW5ITVJ?
M14Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojDTWM2OD1|Nz6xOlQzKM7:TR?=NHj6XZFUSU6JRWK=
786-0MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPwe2NKSzVyPUO3MlI4QTRizszNMo\HV2FPT0WU
MZ2-MELMnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvpTWM2OD1|Nz60OVAyKM7:TR?=MoLkV2FPT0WU
NCI-H510ANIG0W5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkL5TWM2OD1|Nz65OFEzKM7:TR?=NITUUIFUSU6JRWK=
LAN-6MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTN5Lkm1PFIh|ryPM4e4TnNCVkeHUh?=
SW620M1XUR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TDfGlEPTB;M{iuOFk4PCEQvF2=M2jpTHNCVkeHUh?=
LB2241-RCCMlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXtTWM2OD1|OT64NlA2KM7:TR?=Ml7pV2FPT0WU
Detroit562M1v4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7vTWM2OD12MD6xNlY5KM7:TR?=MW\TRW5ITVJ?
HNM4njUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nNTmlEPTB;NECuNVc5OiEQvF2=NGf3dXlUSU6JRWK=
HCT-15NF7yOnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TRNWlEPTB;NECuOVkxPyEQvF2=NHXSdVFUSU6JRWK=
C2BBe1M4rWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTRyLkmxOVch|ryPMVTTRW5ITVJ?
A498NWrIUoNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLiTWM2OD12MT6zNFE2KM7:TR?=MnvOV2FPT0WU
SK-MEL-24NHXu[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoHSTWM2OD12MT60O|I2KM7:TR?=MkLZV2FPT0WU
OVCAR-5MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXXTnBKSzVyPUSxMlc4PjdizszNNFv1WZVUSU6JRWK=
NCI-H1792NUX3OFY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHQTJhFUUN3ME20NU46QDJzIN88US=>NX3vVJl[W0GQR1XS
KOSC-2NVvScJBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTR{LkK2PVkh|ryPM3fPOXNCVkeHUh?=
Mo-TMlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLITWM2OD12Mj64PVU5KM7:TR?=NV3DenpNW0GQR1XS
CFPAC-1M2GwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTR|LkS5OFQh|ryPNHXQcW5USU6JRWK=
CAL-51NETRcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXMXppKSzVyPUSzMlU3ODVizszNM4jmdXNCVkeHUh?=
RH-18MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlviTWM2OD12Mz64NFUh|ryPNIH5TGVUSU6JRWK=
EC-GI-10NGfIT5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXiV5BNUUN3ME20N{45OzR5IN88US=>NH;hUIJUSU6JRWK=
HSC-2M2f6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TZNWlEPTB;NESuNFA6KM7:TR?=NFXhRVJUSU6JRWK=
ML-2NVy3b2VrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jzTmlEPTB;NEWuNlYzOSEQvF2=MWXTRW5ITVJ?
KNS-81-FDMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIrsbHZKSzVyPUS1Mlc{PjVizszNM371cnNCVkeHUh?=
NB6NVrBOFNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTR4LkGxNUDPxE1?MWHTRW5ITVJ?
MCF7M33uSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrvTWM2OD12Nj61OVM{KM7:TR?=MnTnV2FPT0WU
P30-OHKM3XIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvxd|V{UUN3ME20Ok45OTF5IN88US=>NUOxXoQ5W0GQR1XS
BPH-1NUHlfFVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2rmS2lEPTB;NE[uPVgxPSEQvF2=M{DDO3NCVkeHUh?=
U251MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWPJR|UxRTR4Lkm5OEDPxE1?M{T1U3NCVkeHUh?=
MKN1M1vidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrHTlRKSzVyPUS3MlUyOzdizszNM17OXXNCVkeHUh?=
A431NYHVe4NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEX2VYVKSzVyPUS3Mlg{OzhizszNNGjWNFdUSU6JRWK=
C8166Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\4e2lEPTB;NEmuNlA{QSEQvF2=M3XlVHNCVkeHUh?=
HELNEPV[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVznTWtvUUN3ME20PU41ODZ2IN88US=>Mn;yV2FPT0WU
RMG-INUPWfItET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MljTTWM2OD12OT60OFQ1KM7:TR?=MlyzV2FPT0WU
CAL-72NFntUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTR7Lk[wO|Uh|ryPMonlV2FPT0WU
SW962NFnkW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTR7LkmzN|Ih|ryPMUjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).

Protocol(Only for Reference)

Kinase Assay:

[1]

Cellular receptor kinase phosphorylation assay Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.

Cell Assay:

[2]

Cell lines HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
Concentrations 1 nM - 10 μM
Incubation Time 72 hours
Method

Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.

Animal Study:

[3]

Animal Models BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
Formulation 0.5% carboxymethylcellulose (CMC)
Dosages 10, 30 or 100 mg/kg
Administration Oral daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hu-Lowe DD, et al. Clin Cancer Res, 2008, 14(22), 7272-7283.

[2] Rossler, J. et al., Int J Cancer, 2011, 128(11), 2748-2758.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer December 2016 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02762513 Not yet recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center May 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3
NCT02636725 Recruiting Alveolar Soft Part Sarcoma|Soft Tissue Sarcomas Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University  ...more Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University of Miami March 2016 Phase 2

view more

Chemical Information

Download Axitinib SDF
Molecular Weight (MW) 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms AG 013736
Solubility (25°C) * In vitro DMSO 35 mg/mL warming (90.56 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 0.5% CMC 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide

Frequently Asked Questions

  • Question 1
    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

    Answer: Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related VEGFR Products

  • SU5402

    SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

  • Cabozantinib (XL184, BMS-907351)

    Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay.

  • Lenvatinib (E7080)

    Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.

  • Pazopanib

    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

  • Pazopanib HCl (GW786034 HCl)

    Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

    Features:A multi-kinase inhibitor.

Recently Viewed Items

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us